The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Alzheimer's disease drug development pipeline: 2018
Open accessAbstract
Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III. Results: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease‐modifying agent trials and 17 disease‐modifying agent trials in phase II. Twenty‐one trials of disease‐modifying agents in phase II did not require biomarker confirmation for AD at trial entry. Discussion: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the literature review reveals that only a single cholinesterase inhibitor is in Phase II and Phase III clinical trials, for AD management [147,148].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [148]
In the citing paper
“A number of additional pathogenic mechanisms have been described, possibly overlapping with Aβ plaques and NFT formation or induced by them, including inflammation, oxidative damage, iron deregulation, and cholesterol metabolism blood-brain barrier (BBB) dysfunction or α-synuclein toxicity.9-13”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Flagged first, then by citations
Research works printed but not linked: 1
- Lombardo I., 2017, Results from the phase 3 MINDSET STUDY: a global, double‐blind, placebo‐controlled study of intepirdine in mild‐to‐moderate Alzheimer's disease
Cited by
Sorted by citations
Items 201–300 of 701
[11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
Pascoal, T. A., Chamoun, M., Lax, E., Wey, H.-Y., Shin, M., Ng, K. P., Kang, M. S., Mathotaarachchi, S., Benedet, A. L., Therriault, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30653-5 · Cited by 43
Recent Advances in Pharmaceutical Potential of Brown Algal Polysaccharides and their Derivatives
Li, J., Cai, C., Yang, C., Li, J., Sun, T., & Yu, G. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190618143952 · Cited by 42
Gilmour, B. C., Gudmundsrud, R., Frank, J., Hov, A., Lautrup, S., Aman, Y., Røsjø, H. R., Brenner, C., Ziegler, M., Tysnes, O., et al. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111208 · Cited by 44
Su, I., Chang, H., Wang, H.-C., & Tsai, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155459 · Cited by 46
Zhu, L., Li, R., Jiao, S., Wei, J., Yan, Y., Wang, Z. A., Li, J., & Du, Y. (2020) · Marine Drugs · doi:10.3390/md18100488 · Cited by 44
The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial
Burns, D. K., Chiang, C., Welsh-Bohmer, K. A., Brannan, S. K., Culp, M., O’Neil, J., Runyan, G., Harrigan, P., Plassman, B. L., Lutz, M. W., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.010 · Cited by 42
Alzheimer’s Disease “Non-amyloidogenic” p3 Peptide Revisited: A Case for Amyloid-α
Kuhn, A. J., Abrams, B. S., Knowlton, S., & Raskatov, J. A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00160 · Cited by 43
Naringenin alleviates cognition deficits in high‐fat diet‐fed SAMP8 mice
Zhou, T., Liu, L., Wang, Q., & Gao, Y. T. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13375 · Cited by 42
Wang, L., Tan, Y., Yang, X., Kuang, L., & Ping, P. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac080 · Cited by 40
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Zanden, C. M. V., & Chi, E. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 40
Hammoudi, N.-E.-H., Sobhi, W., Attoui, A., Lemaoui, T., Erto, A., & Benguerba, Y. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129845 · Cited by 42
Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models
Trombetta-Lima, M., Sabogal-Guáqueta, A. M., & Dolga, A. M. (2021) · Cell Calcium · doi:10.1016/j.ceca.2021.102362 · Cited by 42
SANE: A sequence combined attentive network embedding model for COVID-19 drug repositioning
Su, X., You, Z., Wang, L., Hu, L., Wong, L., Ji, B., & Zhao, B.-W. (2021) · Applied Soft Computing · doi:10.1016/j.asoc.2021.107831 · Cited by 40
Tarumi, T., Thomas, B. P., Tseng, B. Y., Wang, C., Womack, K. B., Hynan, L. S., Lu, H., Cullum, C. M., & Zhang, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190875 · Cited by 45
Wu, J., Pistolozzi, M., Liu, S., & Tan, W. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115324 · Cited by 40
Modulation of Alzheimer's amyloid β peptide oligomerization and toxicity by extracellular Hsp70
Rivera, I., Capone, R. F., Cauvi, D. M., Arispe, N. J., & Maio, A. D. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0839-0 · Cited by 41
Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force
Gauthier, S. G., Alam, J., Fillit, H. M., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M. N., Salloway, S., Sampaio, C., Sims, J. R., Sperling, B. K., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.12 · Cited by 39
miRNAs Identify Shared Pathways in Alzheimer’s and Parkinson’s Diseases
Sadlon, A., Takousis, P., Alexopoulos, P., Εvangelou, Ε., Prokopenko, I., & Perneczky, R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.006 · Cited by 40
Guo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40
Gupta, S., Parihar, D., Shah, M., Yadav, S., Managori, H., Bhowmick, S., Patil, P. C., Alissa, S. A., Wabaidur, S. M., & Islam, M. A. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.127660 · Cited by 38
Daubner, J., Arshaad, M. I., Henseler, C., Hescheler, J., Ehninger, D., Broich, K., Rawashdeh, O., Papazoglou, A., & Weiergräber, M. (2021) · Neural Plasticity · doi:10.1155/2021/8823383 · Cited by 44
Padilla-Godínez, F. J., Vázquez-García, E. R., Trujillo-Villagrán, M. I., Soto-Rojas, L. O., Palomero‐Rivero, M., Hernández-González, O., Pérez-Eugenio, F., Collazo-Navarrete, O., Arias-Carrión, Ó., & Guerra‐Crespo, M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1570553 · Cited by 42
Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Bazzari, F. H., Abdallah, D. M., & El-Abhar, H. S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190301111120 · Cited by 39
CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
Boumenir, A., Cognat, E., Sabia, S., Hourrègue, C., Lilamand, M., Dugravot, A., Bouaziz-Amar, É., Laplanche, J., Hugon, J., Singh‐Manoux, A., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0481-4 · Cited by 38
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 40
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 42
Singh, C. S. B., Choi, K. B., Munro, L., Wang, H. Y., Pfeifer, C. G., & Jefferies, W. A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103503 · Cited by 36
Ma, C., Wu, Y., Song, L., Yin, L., Yin, J.-J., Wang, Q., Yu, J., & Xiao, B. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355747 · Cited by 37
A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017
Andrisano, V., Naldi, M., Simone, A. D., & Bartolini, M. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1476494 · Cited by 35
Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease
Kim, Y. H., Lee, S.-M., Cho, S., Kang, J., Minn, Y., Park, H., & Choi, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41429-1 · Cited by 37
In Vitro Blood–Brain Barrier-Integrated Neurological Disorder Models Using a Microfluidic Device
Choi, J., Santhosh, M., & Choi, J.-W. (2019) · Micromachines · doi:10.3390/mi11010021 · Cited by 37
Advances in protein misfolding, amyloidosis and its correlation with human diseases
Kundu, D., Prerna, K., Chaurasia, R., Bharty, M. K., & Dubey, V. K. (2020) · 3 Biotech · doi:10.1007/s13205-020-2166-x · Cited by 40
Inhibition of 14-3-3/Tau by Hybrid Small-Molecule Peptides Operating via Two Different Binding Modes
Andrei, S. A., Meijer, F. A., Neves, J. F., Brunsveld, L., Landrieu, I., Ottmann, C., & Milroy, L. ‐. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00118 · Cited by 35
Alzheimer's disease mechanisms in peripheral cells: Promises and challenges
Trushina, E. V. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.008 · Cited by 35
Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors
Shi, C., Peng, W., Zhao, J., Yang, H., Qu, L., Wang, C., Kong, L., & Wang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111961 · Cited by 36
The Ambiguous Role of Microglia in Aβ Toxicity: Chances for Therapeutic Intervention
Merlo, S., Spampinato, S. F., Caruso, G. I., & Sortino, M. A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200131105418 · Cited by 35
Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors
Meden, A., Knez, D., Malikowska‐Racia, N., Brazzolotto, X., Nachon, F., Svete, J., Sałat, K., Grošelj, U., & Gobec, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112766 · Cited by 34
From tissue engineering to engineering tissues: the role and application of in vitro models
Pacheco, D. P., Vargas, N. S., Visentin, S., & Petrini, P. (2020) · Biomaterials Science · doi:10.1039/d0bm01097a · Cited by 37
Chen, Y., Lu, C.-H., Ke, C., Chiu, S.-J., Chang, C., Yang, B., Gelovani, J. G., & Liu, R.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168633 · Cited by 33
Ito, K., Chapman, R., Pearson, S. D., Tafazzoli, A., Yaffe, K. S., & Gurwitz, J. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.29392 · Cited by 35
Chen, Y., Hu, D., Zhao, L., Tang, W., & Li, B. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.339337 · Cited by 35
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 37
The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease
Ehtezazi, T., Rahman, K., Davies, R., & Leach, A. G. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220071 · Cited by 37
Shin, S. J., Jeong, Y.-O., Jeon, S. G., Kim, S., Lee, S.-K., Choi, H. S., Im, C. S., Kim, S. H., Kim, S. H., Park, J. H., et al. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.003 · Cited by 35
Zilony, N., Rosenberg, M., Richman, M., Yehuda, R., Schori, H., Motiei, M., Rahimipour, S., Groisman, A., Segal, E., & Shefi, O. (2019) · Small · doi:10.1002/smll.201904203 · Cited by 34
Rationale for the development of an Alzheimer’s disease vaccine
Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665453 · Cited by 35
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis
Lu, L., Zheng, X., Wang, S., Tang, C., Zhang, Y., Yao, G., Zeng, J., Ge, S., Wen, H., Xu, M., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323497 · Cited by 35
Kulichikhin, K. Y., Fedotov, S. A., Rubel, M. S., Zalutskaya, N. M., Zobnina, A. E., Malikova, O. A., Незнанов, Н. Г., Chernoff, Y. O., & Rubel, A. A. (2021) · Prion · doi:10.1080/19336896.2021.1917289 · Cited by 34
Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease
Ballard, C. G., Atri, A., Boneva, N., Cummings, J. L., Frölich, L., Molinuevo, J. L., Tariot, P. N., & Rakêt, L. L. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.04.001 · Cited by 33
Self-citationKumar, D., Sharma, A., & Sharma, L. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200203101828 · Cited by 36
Zhu, L., Hou, X., Che, X., Zhou, T.-S., Liu, X.-Q., Wu, C., & Yang, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00562-8 · Cited by 33
Zebrafish as a Promising Tool for Modeling Neurotoxin-Induced Alzheimer’s Disease
Thawkar, B. S., & Kaur, G. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00343-z · Cited by 36
Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?
Siafaka, P. I., Okur, M. E., Dilsiz, P., Çağlar, E. Ş., Özgenç, E., Gündoğdu, E., Köprülü, R. E. P., Karantas, I. D., & Okur, N. Ü. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112425 · Cited by 34
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Three Decades of Amyloid Beta Synthesis: Challenges and Advances
Kasim, J. K., Kavianinia, I., Harris, P. W. R., & Brimble, M. A. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00472 · Cited by 32
Singh, R. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200128121920 · Cited by 32
Okuda, M., Fujita, Y., Takada‐Takatori, Y., Sugimoto, H., & Urakami, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240378 · Cited by 32
Abate, G., Vezzoli, M., Polito, L., Guaita, A., Albani, D., Marizzoni, M., Garrafa, E., Marengoni, A., Forloni, G., Frisoni, G. B., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm11010014 · Cited by 31
Self-citationUrsin, F., Timmermann, C., & Steger, F. (2021) · Diagnostics · doi:10.3390/diagnostics11030440 · Cited by 38
Network-based stage-specific drug repurposing for Alzheimer’s disease
Savva, K., Zachariou, M., Bourdakou, M. M., Dietis, N., & Spyrou, G. M. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.013 · Cited by 32
Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease
Sfera, A., Gradini, R., Cummings, M., Diaz, E. L., Price, A. I., & Osorio, C. P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01062 · Cited by 32
Advanced nano delivery system for stem cell therapy for Alzheimer's disease
Pan, Y., Li, L., Cao, N., Liao, J., Chen, H., & Zhang, M. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122852 · Cited by 33
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer’s Disease
Romeiro, L. A. S., Nunes, J. L. D. C., Miranda, C. D. O., Cardoso, G. S. H. R., de Oliveira, A. S., Gandini, A., Kobrlová, T., Soukup, O., Rossi, M., Senger, J., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00071 · Cited by 32
Dementia treatment versus prevention
Perneczky, R. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/rperneczky · Cited by 36
Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice
Castellanos, D. M., Sun, J., Yang, J., Ou, W., Zambon, A. C., Pardridge, W. M., & Sumbria, R. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090852 · Cited by 32
Arnerić, S. P., Kern, V. D., & Stephenson, D. T. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.043 · Cited by 31
Arias, J. J., Tyler, A. M., Oster, B. J., & Karlawish, J. H. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518782955 · Cited by 31
Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304153353 · Cited by 30
Beta-amyloid short- and long-term synaptic entanglement
Lanni, C., Fagiani, F., Racchi, M., Preda, S., Pascale, A., Grilli, M., Allegri, N., & Govoni, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.018 · Cited by 29
Marshall, L. J., Constantino, H., & Seidle, T. (2022) · Animals · doi:10.3390/ani12070863 · Cited by 35
Small Molecule Natural Products and Alzheimer’s Disease
Wu, X., Cai, H., Pan, L., Cui, G., Qin, F., Li, Y., & Cai, Z. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190201153257 · Cited by 29
A metabolic perspective of late onset Alzheimer’s disease
Ettcheto, M., Cano, A. C., Busquets, O., Manzine, P. R., Sánchez‐López, E., Castro-Torres, R. D., Beas‐Zárate, C., Verdaguer, E., García, M. L., Olloquequi, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104255 · Cited by 31
Bae, H. J., Sowndhararajan, K., Park, H.-B., Kim, S.-Y., Kim, S., Kim, D. H., Choi, J. W., Jang, D. S., Ryu, J. H., & Park, S. J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104537 · Cited by 30
Pasieka, A., Panek, D., Jończyk, J., Godyń, J., Szałaj, N., Latacz, G., Tabor, J., Mezeiová, E., Chantegreil, F., Dias, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113397 · Cited by 30
Sex differences in Alzheimer's disease: do differences in tau explain the verbal memory gap?
Banks, S. J., Andrews, M., Digma, L. A., Madsen, J. R., Reas, E. T., Caldwell, J., McEvoy, L. K., Fan, C. C., Dale, A. M., & Brewer, J. B. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.05.013 · Cited by 31
Koychev, I. G., Lawson, J., Chessell, T., Mackay, C. E., Gunn, R. N., Sahakian, B. J., Rowe, J. B., Thomas, A. J., Rochester, L., Chan, D., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024498 · Cited by 31
Yeo, I. J., Lee, M. J., Baek, A., Miller, Z. C., Bhattarai, D., Baek, Y. M., Jeong, H. J., Kim, Y. K., Kim, D., Hong, J. T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54846-z · Cited by 29
Kim, D. Y., Choi, S. H., Lee, J., Kim, H. J., Kim, H., Lee, J. E., Shin, J. Y., & Lee, P. H. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200026 · Cited by 29
Kishimoto, T., Takamiya, A., Liang, K., Funaki, K., Fujita, T., Kitazawa, M., Yoshimura, M., Tazawa, Y., Horigome, T., Eguchi, Y., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100649 · Cited by 30
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 34
Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer’s Disease Agents
Poliseno, V., Chaves, S., Brunetti, L., Loiodice, F., Carrieri, A., Laghezza, A., Tortorella, P., Magalhães, J. D., Cardoso, S. M., Santos, M. A., et al. (2021) · Biomolecules · doi:10.3390/biom11010111 · Cited by 30
Association between exenatide use and incidence of Alzheimer's disease
Zhou, B., Zissimopoulos, J., Nadeem, H., Crane, M. A., Goldman, D. P., & Romley, J. A. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12139 · Cited by 28
Novikova, G., Andrews, S. J., Renton, A. E., & Marcora, E. M. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00449-0 · Cited by 31
Dihydropyrimidinone-derived selenoesters efficacy and safety in an in vivo model of Aβ aggregation
Pereira, F. S. D. O., Barbosa, F. A. R., Canto, R. F. S., Luchese, C., Pinton, S., Braga, A. L., de Azeredo, J. B., Quines, C. B., & Ávila, D. S. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.10.012 · Cited by 29
Algahtani, H. A., Shirah, B. H., Alhazmi, A., Alshareef, A., Bajunaid, M., & Samman, A. S. (2018) · Acta Neurologica Belgica · doi:10.1007/s13760-018-1040-7 · Cited by 28
Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders
Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00223 · Cited by 28
Huang, L., Wu, Y., Yin, H., Yang, X., Yuan, M., & Ning, H. (2020) · Natural Product Research · doi:10.1080/14786419.2020.1753735 · Cited by 28
Wilson, C. A., Fouda, S. E. E., & Sakata, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-72421-9 · Cited by 28
Neves, J. F., Petrvalská, O., Bosica, F., Cantrelle, F., Merzougui, H., O’Mahony, G., Hanoulle, X., Obšil, T., & Landrieu, I. (2020) · FEBS Journal · doi:10.1111/febs.15574 · Cited by 29
Lutz, B. M., & Peng, J. (2018) · Proteomes · doi:10.3390/proteomes6040046 · Cited by 27
Alzheimer Disease Clinical Trials Targeting Amyloid
Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 27
Dynamic nanoassemblies for imaging and therapy of neurological disorders
Zhang, L., Sun, H., Zhao, J., Lee, J., Low, L. E., Gong, L., Chen, Y., Wang, N., Zhu, C., Lin, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113832 · Cited by 27
An insight into prodrug strategy for the treatment of Alzheimer’s disease
Bhilare, N. V., Marulkar, V. S., Kumar, D., Chatap, V. K., Patil, K. S., & Shirote, P. J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02859-1 · Cited by 27
Gu, Z., Chen, H., Zhao, H., Yang, W., Song, Y., Li, X., Wang, Y., Du, D., Liao, H., Pan, W., et al. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2139369 · Cited by 27
Nitrendipine and Dementia: Forgotten Positive Facts?
Novotný, M., Klímová, B., & Vališ, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00418 · Cited by 27
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 28
Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28
Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Dileep, K. V., & Chandra, R. (2019) · Current Drug Targets · doi:10.2174/1389450120666190806153206 · Cited by 26
Lin, S.-Y., Lin, K., Lin, P.-C., Huang, C.-C., Chang, C., Lee, Y., Hsiao, I., Yen, T., Huang, W.-S., Yang, B., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0566-0 · Cited by 26
Mitroshina, Е. V., Yarkov, R. S., Mishchenko, T. A., Krut’, V. G., Gavrish, M. S., Epifanova, E. A., Babaev, A. A., & Vedunova, M. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00582 · Cited by 27
Metadata
- Authors
- Cummings, J., Lee, G., Ritter, A., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Global Alzheimer's Platform Foundation (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 195-214
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6021548
- OpenAlex
- W2918066696
- Cited by
- 697
- References
- 48
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 39 · 2023: 22 · 2022: 55 · 2021: 138 · 2020: 177 · 2019: 170 · 2018: 42
- FWCI
- 91.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, disease-modifying therapy, amyloid biomarkers, prodromal Alzheimer's disease, preclinical Alzheimer's disease, neuropsychiatric symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
